Apogee Therapeutics, Inc.
APGE
Rang în acțiuni
#2364
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Preț acțiune
$135.07
Ultima sincronizare: 2026-09-04
Capitalizare de piață
$8.36B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
137.21%
Țară
US
Tranzacționează Apogee Therapeutics, Inc. (APGE)
Categorie
Healthcare
Raport P/B pentru Apogee Therapeutics, Inc. (APGE)
Raport P/B la data de October 2026 TTM: 8.53
Conform celor mai recente rapoarte financiare și prețului acțiunilor Apogee Therapeutics, Inc., raportul P/B actual (TTM) este 8.53. La sfârșitul anului 2023, compania avea un P/B de 3.73.
Istoricul raportului P/B pentru Apogee Therapeutics, Inc. din 2022 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
